ponesimod - Profile

« Back to Dashboard

What are the generic sources for ponesimod and what is the scope of patent protection?

Ponesimod is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for ponesimod

International Patents:	156
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ponesimod

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ponesimod

Constraining patent/regulatory exclusivity:

RE43728

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ponesimod

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	12,336,980
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	9,062,014		Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	10,220,023
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	11,951,097
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	12,728,116
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	RE43728		Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes

Expired US Patents for ponesimod

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021	8,273,779
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021	9,000,018
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021	8,273,779
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021	9,000,018

EU/EMA Drug Approvals for ponesimod

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Ponvory	ponesimod	EMEA/H/C/005163Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Authorised	no	no	no	2021-05-19

International Patents for ponesimod

Country	Patent Number	Title	Estimated Expiration
Australia	2015359306
Australia	2015359346
Australia	2020202684
Brazil	112017012396
Canada	2964616
Canada	2968180
Chile	2017001457

Supplementary Protection Certificates for ponesimod

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3256125	2290019-5	Sweden		PRODUCT NAME: PONESIMOD AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT. REG. NO/DATE: EU/1/21/1550 20210521; FIRST REG.: GE EU/1/21/1550 20210521
3256125	PA2022505,C3256125	Lithuania		PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125	22C1021	France		PRODUCT NAME: PONESIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1550 20210521
3256125	C202230019	Spain		PRODUCT NAME: PONESIMOD: (R)-5-(3-CLORO-4-(2,3-DIHIDROXIPROPOXI)-BENZO(Z)IDEN)-2-((Z)-PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF AUTHORISATION: 20210519; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1550; DATE OF FIRST AUTHORISATION IN EEA: 20210519
3256125	301174	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
3256125	202240018	Slovenia		PRODUCT NAME: PONESIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF NATIONAL AUTHORISATION: 20210519; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3256125	SPC/GB22/026	United Kingdom		PRODUCT NAME: PONESIMOD ((R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU1/21/1550 (FOR NI) 20210521; UK FURTHER MAS ON IPSUM 20210521

Ponesimod (Ozanimod-class S1P modulator): Investment Scenario and Fundamentals

Last updated: April 26, 2026

What is ponesimod and where does it sit in the pipeline?

Ponesimod (actives: ponesimod) is an oral sphingosine 1-phosphate receptor (S1P) modulator developed for immune-mediated diseases, with the commercial focus on multiple sclerosis and psoriatic disease. The market narrative hinges on (1) MS uptake and persistence, (2) safety and labeling breadth versus class peers, and (3) payer outcomes driven by clinical differentiation and adherence (oral dosing).

What approvals and indications anchor commercialization?

Regulatory status (commercial anchor):

• Europe (EMA): Ponesimod has marketing authorization in the EU for relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease with relapses. [1]
• United States (FDA): Commercial use is tied to FDA action for MS; the investment base case assumes the existence of an approved MS label and ongoing post-approval evidence generation.

Implication for investment fundamentals:

• MS is the revenue engine because RMS populations are large, treatment duration is long, and switching friction is lower once safety and efficacy profiles are established.

---

Which clinical outcomes drive value for MS investors?

S1P modulators typically win on a combination of relapse reduction, MRI lesion effects, and a safety profile that reduces discontinuations. For ponesimod, the valuation hinge points are:

• Relapse rate reduction vs active comparators
• Disability progression signals
• MRI activity reduction
• Safety management that affects persistence, notably bradyarrhythmia risk, macular edema risk, infection risk, and lab monitoring burden.

Key investment logic:

• Revenue durability tracks with discontinuation drivers and label constraints (baseline screening requirements, monitoring cadence, and contraindications). These determine payer authorization ease and real-world adherence.

---

How does ponesimod compare on S1P class economics?

Ponesimod competes within the S1P landscape that includes other oral S1P modulators with overlapping patient segments (RMS) and shared payer scrutiny. The decision for formulary placement typically prices off:

• Clinical differentiation that improves outcomes or reduces monitoring and discontinuations
• Dosing convenience and titration burden
• Hospital and clinic resource impact from baseline and during-treatment monitoring

Investment takeaway:

• The strongest fundamentals occur when ponesimod holds a credible position on either (a) comparable efficacy with lower monitoring burden, or (b) better persistence from a manageable safety profile that reduces early discontinuations.

---

What safety and labeling mechanics matter for commercialization?

S1P drugs typically require structured risk management. For ponesimod investments, commercial constraints generally concentrate in:

• Cardiac effects (initiation monitoring rules)
• Ocular monitoring (macular edema watch, especially for higher-risk patients)
• Infection risk (treatment of active infections, contraindications, monitoring)
• Laboratory and immune surveillance (depending on labeling requirements)

Why this impacts fundamentals:

• Each additional monitoring requirement raises friction for initiation and can reduce physician acceptance, affecting net-to-gross and uptake speed.

---

What is the payer and access pathway likely to look like?

For RMS in major markets, reimbursement patterns for S1P modulators tend to follow:

• Specialty pharmacy distribution
• Prior authorization based on prior therapy use or risk stratification
• Formulary tiering influenced by PBM rebates and clinical guideline alignment
• Outcome-linked adoption when manufacturers offer contracting mechanisms (rebates tied to persistence or disability outcomes, where allowed)

Investment implication:

• Upside comes from payer-friendly access agreements and fast formulary inclusion in top plans.
• Downside comes from slow uptake if monitoring rules or post-marketing safety signals restrict access.

---

What commercial milestones should investors track for ponesimod?

For an investment-grade view, milestones should map to adoption and persistence drivers:

Uptake indicators

• New starts in RMS
• Share shift versus competitors after formulary entry
• Time-to-therapeutic persistence (especially discontinuations in first 6 to 12 months)

Persistence indicators

• Discontinuation reasons and rates
• Real-world adherence to monitoring requirements
• Safety event rates that force label changes or added restrictions

Market execution indicators

• Specialty pharmacy fills and re-fill rate
• Evidence generation (subgroup analyses that support label stability)
• Conversion rate from prior S1P or injectables

---

What are the “fundamentals levers” that move valuation?

1) Clinical durability and switching dynamics

• If ponesimod demonstrates durable relapse control and stable MRI outcomes, it attracts longer therapy duration.
• If safety management stays predictable, switching away due to early tolerability issues declines.

2) Safety label stability

• Label expansions or tightening rules influence prescribing and payer authorization.
• Post-marketing signals that drive additional monitoring or contraindications can reduce access.

3) Competitive positioning in RMS

• S1P class competition pushes manufacturers to trade rebate structure for formulary placement.
• Sustained performance in head-to-head-like evidence (or robust indirect comparisons) affects formulary inclusion.

4) Cost and contracting

• Discounts can accelerate adoption, but compress margin.
• Outcome-based contracting improves net revenue stability if endpoints track reimbursement.

---

What investment scenarios best fit ponesimod?

Base case (most likely)

• Steady RMS penetration, supported by tolerable risk management and stable label.
• Incremental share gains within S1P class rather than a category-wide surge.
• Net sales growth paced by payer inclusion and physician adoption cycle.

What makes this base case plausible:

• Long disease duration and oral dosing support persistence.
• Once a patient is on an S1P modulator, switching typically requires compelling reasons.

Upside case

• Improved persistence profile in real-world data versus peers.
• Faster and broader formulary coverage via payer contracting.
• Evidence supports additional patient subgroups within RMS with acceptable safety monitoring.

Upside drivers to watch:

• Lower early discontinuation rates
• Higher re-fill persistence
• Positive updates in post-marketing safety or adherence programs

Downside case

• Safety signals raise the monitoring burden or trigger more restrictive labeling.
• Payer access tightens due to budget impact concerns or unfavorable contracting outcomes.
• Competitive efficacy or safety differentiation shifts share away.

Downside drivers to watch:

• Early discontinuations due to tolerability
• Formulary exclusions or step-therapy requirements
• Label restrictions that increase friction

---

What due diligence should investors prioritize (non-negotiable items)?

1. Label scope stability and REMS-like burden (if any) that affects clinic workflow.
2. Real-world persistence (especially first-year discontinuation) and documented adverse event rates.
3. Net pricing and rebate pressure in RMS formularies, including specialty pharmacy economics.
4. Trial and post-marketing evidence cadence that supports continued indication breadth.

---

Key Takeaways

• Ponesimod’s investment profile is driven by RMS adoption and persistence, not by one-time trial readouts.
• The critical valuation levers are real-world discontinuation, label stability, and payer access friction created by safety monitoring requirements.
• Competitive outcomes within the S1P class typically determine share trajectory, with contracting and net pricing shaping margin more than gross list price.
• The best risk-adjusted path is a setup where ponesimod demonstrates stable safety management and persistent disease control that supports long duration therapy and reduces payer resistance. [1]

---

FAQs

1) Is ponesimod positioned primarily for multiple sclerosis revenue?

Yes. The approved EU commercial anchor is relapsing forms of multiple sclerosis, which is the largest and most durable revenue pool among current S1P modulator use cases. [1]

2) What is the biggest commercial risk for ponesimod?

The biggest risk is persistence risk from safety events or monitoring burdens that increase early discontinuation and reduce payer and physician willingness to initiate.

3) How does ponesimod’s oral dosing affect fundamentals?

Oral administration usually supports adherence and persistence, reducing switching friction compared with injectables, assuming safety and monitoring requirements stay manageable.

4) What typically determines payer access for S1P modulators in RMS?

Payer decisions usually track budget impact, net pricing after rebates, and clinical guideline alignment, with prior authorization often tied to disease activity and prior therapy use.

5) What evidence would most change an investment view on ponesimod?

Evidence that shifts assumptions about real-world discontinuation, safety label stability, and adherence/persistence would most materially change the fundamentals.

---

References

[1] European Medicines Agency. (n.d.). Ponesimod: EPAR product information and summary. European Union. https://www.ema.europa.eu/ (accessed 2026-04-26)